Watchlist

•

	DJIA F	24,311	91	0.38%
	S&P F	2,727.00	7.50	0.28%
	NASDAQ F	7,083.25	22.75	0.32%
	Gold	1,253.20	2.20	0.18%
	Silver	16.20	0.041	0.25%
	Crude Oil	73.48	0.03	0.04%

S&P 500 Movers(%)

Latest NewsAll Times Eastern

9:05a
Updated How the opioid epidemic is exacerbating a U.S. labor-market shortage
9:00a
An investing playbook for 2018’s 2nd half — with how U.S. stocks stand apart
8:57a
Updated How blood-testing startups are pitching themselves after the Theranos scandal
8:56a
Updated Meet the one patient who will get access to this experimental ALS therapy before it’s approved
8:56a
Updated Amazon acquisition of online pharmacy startup PillPack sends health-care stocks into a nose dive
8:55a
Gold improves but still on track for 6% quarterly retreat
8:53a
Updated Mortgage rates slump as trade fears weigh on a housing market that’s running dry
8:51a
Trump reportedly wants U.S. to quit the WTO | Kudlow jawbones the Fed
8:51a
Synlogic started at outperform with $18 stock price target at Oppenheimer
8:51a
Alpine Immune Sciences started at outperform with $13 stock price target at Oppenheimer

|

SYBX U.S.: Nasdaq

Synlogic Inc.

Watchlist CreateSYBXAlert

SYBXUSAfter HoursBack To Top

Last Updated: Jun 28, 2018 4:42 p.m. EDT Delayed quote

^$ 9.53

0.00

0.00%

After Hours Volume:

542

Close	Chg	Chg %
$9.53	0.10	1.06%	0.10 1.06%

Advanced Charting

$
%
Vol

Advanced Charting

80.82% vs Avg.

Volume: 101K 65 Day Avg. - 125K

Open: 9.42

Close: 9.53

9.32 Day Low/High 9.68

Day Range

8.73 52 Week Low/High 23.00

Customize MarketWatch

Have Watchlists? Log in to see them here or sign up to get started.

Create Account … or Log In

	Symbol Company	Price Chg/Chg %

(Go to Your Watchlist)

No Items in Watchlist

There are currently no items in this Watchlist.

Add Tickers

No Saved Watchlists

Create a list of the investments you want to track.

Create Watchlist …or try this starter list

Uh oh

Something went wrong while loading Watchlist.

Go to Watchlist

No Recent Tickers

Visit a quote page and your recently viewed tickers will be displayed here.

Open $9.42
Day Range 9.32 - 9.68
52 Week Range 8.73 - 23.00
Market Cap $242.55M
Shares Outstanding 25.45M
Public Float 15.91M
Beta 0.34
Rev. per Employee $9.14K
P/E Ratio n/a
EPS $-6.10
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 708.08K 06/15/18
% of Float Shorted 4.45%
Average Volume 124.95K

5 Day	-7.48%
1 Month	1.38%
3 Month	1.60%
YTD	-1.75%
1 Year	-18.48%

MarketWatch
Other Dow Jones

Synlogic started at outperform with $18 stock price target at Oppenheimer

Synlogic started at outperform with $18 stock price target at Oppenheimer

Jun. 29, 2018 at 8:51 a.m. ET
by Tomi Kilgore

Mirna Therapeutics downgraded to perform from outperform at Oppenheimer

Sep. 22, 2016 at 8:17 a.m. ET
by Tomi Kilgore

Mima Therapeutics downgraded to market perform from outperform at Leerink Partners

Aug. 16, 2016 at 7:15 a.m. ET
by Tomi Kilgore

The Daily Startup: Market Turbulence Puts Biotech IPOs in Question

Oct. 8, 2015 at 9:42 a.m. ET
on The Wall Street Journal

Other News
Press Releases

Synlogic Inc Initiated with a Buy at Oppenheimer

Synlogic Inc (NASDAQ: SYBX) received a Buy rating and a $18 price target from Oppenheimer ...[...]

Jun. 28, 2018 at 4:08 p.m. ET
on SmarterAnalyst

Synlogic offers new Synthetic Biologic preclinical data

Synlogic offers new Synthetic Biologic preclinical data

Jun. 25, 2018 at 1:06 p.m. ET
on Seeking Alpha

H.C. Wainwright Reiterates Their Buy Rating on Synlogic Inc

In a report released yesterday, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...[...]

Jun. 12, 2018 at 11:06 a.m. ET
on SmarterAnalyst

Why Synlogic (SYBX) Could Be a Potential Winner

Synlogic (SYBX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

Jun. 5, 2018 at 9:00 a.m. ET
on Zacks.com

The Eleven: Viking Skyrockets, Global Blood Is Fueling

The Eleven: Viking Skyrockets, Global Blood Is Fueling

Jun. 4, 2018 at 1:02 a.m. ET
on Seeking Alpha

Synlogic (SYBX) Enters Oversold Territory

Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

May. 24, 2018 at 7:38 a.m. ET
on Zacks.com

H.C. Wainwright Thinks Synlogic Inc’s Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synlogic Inc (NASDAQ: SYBX) today ...[...]

May. 22, 2018 at 7:22 a.m. ET
on SmarterAnalyst

3 Young Biotechs Positioned To Upend Medicine

3 Young Biotechs Positioned To Upend Medicine

May. 17, 2018 at 10:51 a.m. ET
on Seeking Alpha

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics

May. 16, 2018 at 3:55 a.m. ET
on Seeking Alpha

Lucky Seven: Achaogen Likely To Bounce Back

Lucky Seven: Achaogen Likely To Bounce Back

May. 14, 2018 at 8:19 a.m. ET
on Seeking Alpha

Synlogic Inc Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Synlogic Inc (NASDAQ: SYBX) today ...[...]

May. 11, 2018 at 7:33 a.m. ET
on SmarterAnalyst

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

Lucky Seven: Omeros Moves, Array Biopharma May Be Next

May. 8, 2018 at 3:02 p.m. ET
on Seeking Alpha

Institutional Top Ideas Series: Orbimed Advisors

Institutional Top Ideas Series: Orbimed Advisors

May. 4, 2018 at 3:18 a.m. ET
on Seeking Alpha

Lucky Seven: An Introduction To My Top Biotechnology Picks

Lucky Seven: An Introduction To My Top Biotechnology Picks

May. 3, 2018 at 5:28 a.m. ET
on Seeking Alpha

Synlogic (SYBX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow

Mar. 29, 2018 at 1:05 p.m. ET
on Seeking Alpha

Synlogic to launch Phase 1/2 study of SYNB1618 in H2

Mar. 20, 2018 at 4:12 p.m. ET
on Seeking Alpha

Premarket analyst action - healthcare

Mar. 19, 2018 at 8:47 a.m. ET
on Seeking Alpha

Why Synlogic (SYBX) Might Surprise This Earnings Season

Mar. 19, 2018 at 8:39 a.m. ET
on Zacks.com

Biotech Forum Daily Digest For March 12th

Mar. 12, 2018 at 10:47 a.m. ET
on Seeking Alpha

Synlogic (SYBX) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow

Feb. 16, 2018 at 1:19 p.m. ET
on Seeking Alpha

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

Jun. 25, 2018 at 7:10 a.m. ET
on BusinessWire - BZX

Synlogic Joins Russell 3000® Index

Jun. 25, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

Jun. 11, 2018 at 4:02 p.m. ET
on BusinessWire - BZX

Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

Jun. 4, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update

May. 15, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic Announces Leadership Change

May. 10, 2018 at 4:10 p.m. ET
on BusinessWire - BZX

Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria

Apr. 25, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria

Apr. 18, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting

Apr. 16, 2018 at 4:02 p.m. ET
on BusinessWire - BZX

Synlogic Announces Registered Direct Offering of Common Stock

Apr. 6, 2018 at 8:30 a.m. ET
on BusinessWire - BZX

Synlogic Doses First Patient in Phase 1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

Apr. 2, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic to Present at the 17th Annual Needham Healthcare Conference

Mar. 21, 2018 at 5:05 p.m. ET
on BusinessWire - BZX

Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Mar. 20, 2018 at 4:02 p.m. ET
on BusinessWire - BZX

Synlogic to Present Data at the American Association for Cancer Research 2018 Annual Meeting

Mar. 19, 2018 at 4:16 p.m. ET
on BusinessWire - BZX

Synlogic Presents Clinical and Preclinical Data from Synthetic Biotic™Medicine Programs for Treatment of Inborn Errors of Metabolism at Annual Meeting of The Society for Inherited Metabolic Disorders

Mar. 12, 2018 at 7:00 a.m. ET
on BusinessWire - BZX

Synlogic to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference

Mar. 5, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Changes to its Board of Directors: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry

Feb. 20, 2018 at 8:01 a.m. ET
on Marketwired

SynlogicPresents Data from Immuno-Oncology Development Program Demonstrating Potent Anti-Tumor Immunity Following Administration of Novel STING Agonist-producing Synthetic Biotic™ Medicine

Feb. 13, 2018 at 8:01 a.m. ET
on BusinessWire - BZX

Synlogic to Present at the Leerink Partners 7th Annual Global Healthcare Conference

Feb. 8, 2018 at 4:06 p.m. ET
on BusinessWire - BZX

Synlogic Announces Underwriters’ Option Exercise in Full

Jan. 31, 2018 at 4:05 p.m. ET
on BusinessWire - BZX

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development platform for synthetic biotic medicines. It focuses on metabolic diseases with the potential to be corrected following oral delivery of a living medicine to the gut. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 5 Full Ratings

Benzinga's Top Upgrades, Downgrades For March 19, 2018

Mar. 19, 2018 at 9:11 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For January 29, 2018

Jan. 29, 2018 at 9:19 a.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For November 28, 2017

Nov. 28, 2017 at 8:59 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Momenta Pharmaceuticals Inc.	-0.50%	$1.54B
Melinta Therapeutics Inc.	2.36%	$364.06M

Competitor Data Provided By